Grifols, S.A. (GIKLY)
OTCMKTS
· Delayed Price · Currency is USD
5.33
0.00 (0.00%)
May 27, 2025, 4:00 PM EDT
Grifols Revenue
Grifols had revenue of 1.79B EUR in the quarter ending March 31, 2025, with 9.85% growth. This brings the company's revenue in the last twelve months to 7.37B, up 10.76% year-over-year. In the year 2024, Grifols had annual revenue of 7.21B with 9.41% growth.
Revenue (ttm)
7.37B EUR
Revenue Growth
+10.76%
P/S Ratio
0.84
Revenue / Employee
309.34K EUR
Employees
23,833
Market Cap
6.71B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 7.21B | 620.41M | 9.41% |
Dec 31, 2023 | 6.59B | 528.01M | 8.71% |
Jan 1, 2023 | 6.06B | 1.13B | 22.92% |
Dec 31, 2021 | 4.93B | -406.92M | -7.62% |
Dec 31, 2020 | 5.34B | 241.35M | 4.73% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 70.00M |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
Silence Therapeutics | 27.70M |
BioStem Technologies | 332.45M |
Grifols News
- 7 days ago - Grifols: If This Works Out, It Has Massive Upside - Seeking Alpha
- 16 days ago - Grifols S.A. reports Q1 results - Seeking Alpha
- 17 days ago - Grifols, S.A. (GRFS) Q1 2025 Earnings Conference Call Transcript - Seeking Alpha
- 17 days ago - Grifols says on course to meet 2025 outlook as net profit triples - Reuters
- 17 days ago - Grifols, S.A. 2025 Q1 - Results - Earnings Call Presentation - Seeking Alpha
- 5 weeks ago - Grifols: A Market Setback Turns Into Buying Opportunity - Seeking Alpha
- 5 weeks ago - White Falcon Capital Q1 2025 Partner's Letter - Seeking Alpha
- 7 weeks ago - IBL International collaborates with Grifols on advanced biomarker panels - Business Wire